Actively Recruiting
Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis in Cirrhosis Patients With and Without Hepatocellular Carcinoma
Led by Mansoura University · Updated on 2025-08-20
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of anticoagulant medications in patients with portal vein thrombosis who also have cirrhosis, with or without hepatocellular carcinoma (HCC). This phase 4 study aims to assess the effectiveness and safety of anticoagulant therapy in this group, focusing on how these treatments affect portal vein thrombosis over time. Participants will be assigned to one of three groups: those with HCC receiving anticoagulants such as Enoxaparin, Warfarin, or Apixaban; cirrhotic patients with benign thrombus on similar anticoagulants; and cirrhotic patients with thrombosis who are not receiving anticoagulant therapy. The study monitors these groups to compare outcomes related to their treatment status. Throughout the six-month study period, researchers will closely monitor portal vein thrombosis and evaluate the impact of anticoagulant therapy. Participants will undergo regular assessments to track their condition and any potential side effects. The study will collect data on the safety and performance of these medications in managing thrombosis within this patient population.
CONDITIONS
Brief Title
Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with portal vein thrombosis and cirrhosis
- Cirrhosis classified as Child A or Child B
- Age between 18 and 70 years
- With or without hepatocellular carcinoma (HCC)
You will not qualify if you...
- Platelet count below 10,000
- Creatinine level greater than 1.9
- Presence of Budd-Chiari syndrome
- Uncontrolled active bleeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 6 months
Participants receive anticoagulant therapy with Enoxaparin, warfarin, or apixaban or no anticoagulant based on group assignment.
Trial Site Locations
Total: 1 location
1
Mansoura University Hospitals
Al Mansurah, Dakahlia Governorate, Egypt, 35511
Actively Recruiting
Research Team
D
Dalia Elsayed Ganady, MBBS
H
Hatem Elalfy, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here